Fesoterodine

BreastfeedingPediatric
  • TRADE NAME: Toviaz (Pfizer)
  • INDICATIONS: Overactive bladder syndrome; urinary incontinence, urgency and frequency
  • CLASS: Muscarinic antagonist
  • HALF-LIFE: 7 hours; 4 hours (oral)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Amantadine, Anticholinergics, Antidepressants, Antimuscarinics, Atazanavir, Botulinum Toxin (A & B), Carbamazepine, Cinacalcet, Clarithromycin, Conivaptan, CYP2D6 inhibitors, CYP3A4 inhibitors, CYP3AF inhibitors, Darunavir, Dasatinib, Deferasirox, Delavirdine, Duloxetine, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, PEG-Interferon, Phenobarbital, Phenytoin, Pramlintide, Rifampin, Ritonavir, Saquinavir, Secretin, St John's Wort, Telithromycin, Terbinafine, Tipranavir, Tocilizumab, Voriconazole

PREGNANCY CATEGORY: C

Contra-indicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.

Our database has 31 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fesoterodine in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top